title: Relevance of systems pharmacology in drug discovery.
abstract: The pharmaceutical industry is in the process of re-inventing its pipeline in an attempt to overcome its increasing phase II and III attrition rates. Here, we describe how systems pharmacology can be used as a risk assessment tool to alleviate this problem before bringing in larger investments. We propose that this translational research tool could provide a valuable, complementary addition to other emerging innovative approaches for target identification and validation in discovery and, ultimately, for aiding clinical trial optimization.
authors.affiliation: Translational Research, Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer PGRD, Sandwich, Kent CT13 9NJ, UK. Lourdes.Cucurull-Sanchez@Pfizer.com
authors.forename: Lourdes
authors.initials: L
authors.lastname: Cucurull-Sanchez
authors.forename: Karen G
authors.initials: KG
authors.lastname: Spink
authors.forename: Sterghios Athanasios
authors.initials: SA
authors.lastname: Moschos
mesh_terms: D003198:Computer Simulation; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D051550:I-kappa B Kinase / Q000037:antagonists & inhibitors / Q000276:immunology; D008954:Models, Biological; D016328:NF-kappa B / Q000276:immunology / Q000378:metabolism; D010601:Pharmacology, Clinical / Q000379:methods*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000201:enzymology / Q000276:immunology; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology; D049490:Systems Biology / Q000379:methods*
chemical_list: D016328:NF-kappa B; D051550:I-kappa B Kinase